All In MedTech

FDA Clearance Tracker · P090013

REVO MRI SURESCAN IPG AND PACING SYSTEM

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Feb 8, 2011 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Feb 8, 2011

Approved

Time to decision

609 days

Received Jun 9, 2009. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P090013
Device name
REVO MRI SURESCAN IPG AND PACING SYSTEM
Applicant location
Mounds View, MN
Received
Jun 9, 2009
Decided
Feb 8, 2011
Decision
Approved
Supplements
325 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code LWP

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE REVO MRISURESCAN PACING SYSTEM, WHICH CONSISTS OF THE MEDTRONIC REVO MRI¿ SURESCAN¿ MODEL RVDR01 IPG, THE MEDTRONIC CAPSUREFIX MRI¿ SURESCAN¿ 5086MRI LEAD, AND THE REVO MRI¿ SOFTWARE APPLICATION MODEL SW018. THIS SYSTEM IS INDICATED AS FOLLOWS:THE MEDTRONIC REVO MRI¿ SURESCAN¿ MODEL RVDR01 IPG IS INDICATED FOR USE AS A SYSTEM CONSISTING OF A REVO MRI SURESCAN IPG IMPLANTED WITH TWO CAPSURE FIX MRI¿SURESCAN¿ 5086MRI LEADS. A COMPLETE SYSTEM IS REQUIRED FOR USE IN THE MRI ENVIRONMENT.THE MEDTRONIC REVO MRI¿ SURESCAN¿ MODEL RVDR01 IPG IS INDICATED FOR THEFOLLOWING:1) RATE ADAPTIVE PACING IN PATIENTS WHO MAY BENEFIT FROM INCREASED PACING RALESCONCURRENT WITH INCREASES IN ACTIVITY;2) ACCEPTED PATIENT CONDITIONS WARRANTING CHRONIC CARDIAC PACING INCLUDE:A) SYMPTOMATIC PAROXYSMAL OR PERMANENT SECOND-DEGREE OR THIRD-DEGREE AV BLOCK;B) SYMPTOMATIC BILATERAL BUNDLE BRANCH BLOCK;C) SYMPTOMATIC PAROXYSMAL OR TRANSIENT SINUS NODE DYSFUNCTIONS WITH OR WITHOUT ASSOCIATED AV CONDUCTION DISORDERS; ANDD) BRADYCARDIA-TACHYCARDIA SYNDROME TO PREVENT SYMPTOMATIC BRADYCARDIA OR SOMEFORMS OF SYMPTOMATIC TACHYARRHYTHMIAS...(SEE APPROVAL ORDER FOR ADD'L DETAIL)

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code LWP. The earliest in FDA's data is P780009, decided Mar 27, 1979.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Medtronic, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.